​
​

AbCellera Biologics (ABCL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ABCL Stock Forecast

AbCellera Biologics stock forecast is as follows: an average price target of $20.17 (represents a 644.28% upside from ABCL’s last price of $2.71) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.

ABCL Price Target

The average price target for AbCellera Biologics (ABCL) is $20.17 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $34.00 to $5.00. This represents a potential 644.28% upside from ABCL's last price of $2.71.

ABCL Analyst Ratings

Buy

According to 10 Wall Street analysts, AbCellera Biologics's rating consensus is 'Buy'. The analyst rating breakdown for ABCL stock is 0 'Strong Buy' (0.00%), 7 'Buy' (70.00%), 3 'Hold' (30.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

AbCellera Biologics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2024Gary NachmanBMO Capital$5.00$2.7382.82%84.50%
Aug 23, 2024Scott SchoenhausKeyBanc$5.00$2.6092.68%84.50%
May 08, 2024Scott SchoenhausKeyBanc$7.00$3.8482.29%158.30%
Jan 06, 2023-Leerink Partners$18.00$9.6387.01%564.21%
Dec 15, 2022Andrea TanGoldman Sachs$30.00$10.13196.15%1007.01%
Nov 16, 2022-Truist Financial$29.00$14.49100.14%970.11%
Aug 10, 2022-Credit Suisse$34.00$11.85186.92%1154.61%
Row per page
Go to

The latest AbCellera Biologics stock forecast, released on Nov 05, 2024 by Gary Nachman from BMO Capital, set a price target of $5.00, which represents a 82.82% increase from the stock price at the time of the forecast ($2.73), and a 84.50% increase from ABCL last price ($2.71).

AbCellera Biologics Price Target by Period

1M3M12M
# Anlaysts123
Avg Price Target$5.00$5.00$5.67
Last Closing Price$2.71$2.71$2.71
Upside/Downside84.50%84.50%109.23%

In the current month, the average price target of AbCellera Biologics stock is $5.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 84.50% increase as opposed to AbCellera Biologics's last price of $2.71. This month's average price target is down 0.00% compared to last quarter, and down -11.82% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 05, 2024BMO CapitalOutperformOutperformHold
Aug 23, 2024KeyBancOverweightOverweightHold
Aug 20, 2024BenchmarkBuyHoldDowngrade
Jun 28, 2024Cowen & Co.BuyBuyHold
May 08, 2024KeyBancOverweightOverweightHold
Aug 31, 2023BenchmarkBuyBuyHold
Jan 06, 2023SVB LeerinkOutperformOutperformHold
Dec 15, 2022Goldman Sachs-BuyInitialise
Nov 16, 2022Credit SuisseOutperformNeutralInitialise
Nov 16, 2022RBC Capital-OutperformInitialise
Row per page
Go to

AbCellera Biologics's last stock rating was published by BMO Capital on Nov 05, 2024. The company gave ABCL a "Outperform" rating, the same as its previous rate.

AbCellera Biologics Financial Forecast

AbCellera Biologics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
Revenue---------$6.60M$10.06M$12.19M$21.55M$101.38M$45.92M$316.58M$139.33M$5.51M$27.64M$202.74M$207.91M
Avg Forecast$13.34M$12.54M$12.87M$11.81M$7.58M$7.68M$10.12M$10.73M$8.89M$11.48M$12.38M$12.11M$50.80M$74.96M$53.59M$219.75M$122.05M$12.60M$71.51M$203.18M$194.59M
High Forecast$21.84M$20.54M$21.07M$19.08M$10.42M$8.08M$10.12M$10.80M$11.30M$13.50M$20.27M$19.83M$83.20M$74.96M$53.59M$219.75M$122.05M$12.60M$71.51M$203.18M$194.59M
Low Forecast$6.60M$6.21M$6.37M$4.53M$5.02M$7.28M$10.12M$10.66M$6.96M$8.68M$6.12M$5.99M$25.14M$74.96M$53.59M$219.75M$122.05M$12.60M$71.51M$203.18M$194.59M
# Analysts111284347854434354545
Surprise %---------0.58%0.81%1.01%0.42%1.35%0.86%1.44%1.14%0.44%0.39%1.00%1.07%

AbCellera Biologics's average Quarter revenue forecast for Dec 23 based on 7 analysts is $8.89M, with a low forecast of $6.96M, and a high forecast of $11.30M. ABCL's average Quarter revenue forecast represents a 34.77% increase compared to the company's last Quarter revenue of $6.60M (Sep 23).

AbCellera Biologics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts111284347854434354545
EBITDA---------$-33.54M$-32.39M$-54.38M$-4.66M$46.61M$-820.00K$235.12M$89.57M$-20.77M$2.14M$165.45M$121.26M
Avg Forecast$2.40M$2.25M$2.31M$2.12M$1.36M$1.38M$1.82M$1.93M$1.60M$2.06M$2.22M$2.17M$9.12M$13.71M$9.80M$150.16M$22.33M$2.30M$13.08M$169.81M$35.60M
High Forecast$3.92M$3.69M$3.78M$3.43M$1.87M$1.45M$1.82M$1.94M$2.03M$2.42M$3.64M$3.56M$14.94M$13.71M$9.80M$180.19M$22.33M$2.30M$13.08M$203.77M$35.60M
Low Forecast$1.19M$1.11M$1.14M$813.96K$902.00K$1.31M$1.82M$1.91M$1.25M$1.56M$1.10M$1.08M$4.51M$13.71M$9.80M$120.12M$22.33M$2.30M$13.08M$135.85M$35.60M
Surprise %----------16.27%-14.57%-25.01%-0.51%3.40%-0.08%1.57%4.01%-9.01%0.16%0.97%3.41%

4 analysts predict ABCL's average Quarter EBITDA for Dec 22 to be $9.12M, with a high of $14.94M and a low of $4.51M. This is -80.43% lower than AbCellera Biologics's previous annual EBITDA (Sep 22) of $46.61M.

AbCellera Biologics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts111284347854434354545
Net Income---------$-28.61M$-30.53M$-40.11M$-29.89M$26.62M$-6.79M$168.57M$59.95M$-21.38M$-2.32M$117.22M$117.00M
Avg Forecast$-37.35M$-36.36M$-39.31M$-37.35M$-39.31M$-36.69M$-35.38M$-37.00M$-33.87M$-35.71M$-39.60M$-37.91M$2.87M$18.45M$874.71K$107.35M$59.99M$-10.30M$24.27M$120.31M$186.34M
High Forecast$-12.82M$-12.48M$-13.49M$-31.12M$-26.21M$-12.59M$-12.14M$-12.70M$-24.19M$-27.47M$-13.59M$-13.01M$5.25M$18.45M$874.71K$128.83M$59.99M$-10.30M$24.27M$144.37M$186.34M
Low Forecast$-68.31M$-66.51M$-71.90M$-41.50M$-44.56M$-67.11M$-64.71M$-67.66M$-48.39M$-54.94M$-72.42M$-69.33M$984.43K$18.45M$874.71K$85.88M$59.99M$-10.30M$24.27M$96.24M$186.34M
Surprise %---------0.80%0.77%1.06%-10.42%1.44%-7.76%1.57%1.00%2.08%-0.10%0.97%0.63%

AbCellera Biologics's average Quarter net income forecast for Dec 22 is $2.87M, with a range of $984.43K to $5.25M. ABCL's average Quarter net income forecast represents a -89.23% decrease compared to the company's last Quarter net income of $26.62M (Sep 22).

AbCellera Biologics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts111284347854434354545
SG&A---------$17.84M$19.36M$18.91M$15.71M$16.88M$17.53M$16.64M$14.72M$12.49M$12.50M$9.00M$8.03M
Avg Forecast$7.09M$6.67M$6.84M$6.28M$4.03M$4.08M$5.38M$5.70M$4.73M$6.10M$6.58M$6.44M$27.00M$39.84M$28.48M$10.60M$64.87M$6.70M$38.01M$9.24M$103.43M
High Forecast$11.61M$10.92M$11.20M$10.14M$5.54M$4.30M$5.38M$5.74M$6.01M$7.18M$10.77M$10.54M$44.22M$39.84M$28.48M$12.71M$64.87M$6.70M$38.01M$11.08M$103.43M
Low Forecast$3.51M$3.30M$3.38M$2.41M$2.67M$3.87M$5.38M$5.66M$3.70M$4.61M$3.25M$3.18M$13.36M$39.84M$28.48M$8.48M$64.87M$6.70M$38.01M$7.39M$103.43M
Surprise %---------2.92%2.94%2.94%0.58%0.42%0.62%1.57%0.23%1.87%0.33%0.97%0.08%

AbCellera Biologics's average Quarter SG&A projection for Dec 23 is $4.73M, based on 7 Wall Street analysts, with a range of $3.70M to $6.01M. The forecast indicates a -73.50% fall compared to ABCL last annual SG&A of $17.84M (Sep 23).

AbCellera Biologics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
# Analysts111284347854434354545
EPS---------$-0.10$-0.11$-0.14$-0.10$0.09$-0.02$0.59$0.21$-0.08$-0.01$0.43$0.43
Avg Forecast$-0.13$-0.12$-0.13$-0.13$-0.13$-0.12$-0.12$-0.13$-0.11$-0.12$-0.13$-0.13$0.01$0.06-$0.40$0.20$-0.04$0.08$0.36$0.63
High Forecast$-0.04$-0.04$-0.05$-0.11$-0.09$-0.04$-0.04$-0.04$-0.08$-0.09$-0.05$-0.04$0.02$0.06-$0.40$0.20$-0.04$0.08$0.36$0.63
Low Forecast$-0.23$-0.23$-0.24$-0.14$-0.15$-0.23$-0.22$-0.23$-0.16$-0.19$-0.25$-0.24-$0.06-$0.40$0.20$-0.04$0.08$0.36$0.63
Surprise %---------0.82%0.82%1.09%-10.28%1.44%-8.01%1.48%1.03%2.29%-0.12%1.19%0.68%

According to 4 Wall Street analysts, AbCellera Biologics's projected average Quarter EPS for Dec 22 is $0.01, with a low estimate of - and a high estimate of $0.02. This represents a -89.19% decrease compared to ABCL previous annual EPS of $0.09 (Sep 22).

AbCellera Biologics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.69$70.0010044.93%Buy
CVACCureVac$2.50$29.001060.00%Buy
ABCLAbCellera Biologics$2.71$20.17644.28%Buy
VIRVir Bio$6.93$26.60283.84%Buy
IOVAIovance Biotherapeutics$8.19$21.00156.41%Buy
SRPTSarepta Therapeutics$106.62$169.0658.56%Buy
PTCTPTC Therapeutics$39.36$46.5018.14%Hold
KRYSKrystal Biotech$177.85$191.007.39%Buy
MDGLMadrigal Pharmaceuticals$314.17$315.750.50%Buy

ABCL Forecast FAQ

Is AbCellera Biologics a good buy?

Yes, according to 10 Wall Street analysts, AbCellera Biologics (ABCL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 70.00% of ABCL's total ratings.

What is ABCL's price target?

AbCellera Biologics (ABCL) average price target is $20.17 with a range of $5 to $34, implying a 644.28% from its last price of $2.71. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will AbCellera Biologics stock go up soon?

According to Wall Street analysts' prediction for ABCL stock, the company can go up by 644.28% (from the last price of $2.71 to the average price target of $20.17), up by 1154.61% based on the highest stock price target, and up by 84.50% based on the lowest stock price target.

Can AbCellera Biologics stock reach $4?

ABCL's average twelve months analyst stock price target of $20.17 supports the claim that AbCellera Biologics can reach $4 in the near future.

What is AbCellera Biologics's current price target trend?

1 Wall Street analyst forecast a $5 price target for AbCellera Biologics (ABCL) this month, up 84.50% from its last price of $2.71. Compared to the last 3 and 12 months, the average price target increased by 84.50% and increased by 109.23%, respectively.

What are AbCellera Biologics's analysts' financial forecasts?

AbCellera Biologics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $36.1M (high $39.42M, low $33.07M), average EBITDA is $6.48M (high $7.08M, low $5.94M), average net income is $-148M (high $-63.646M, low $-244M), average SG&A $19.19M (high $20.95M, low $17.58M), and average EPS is $-0.503 (high $-0.216, low $-0.828). ABCL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $50.56M (high $82.54M, low $23.7M), average EBITDA is $9.08M (high $14.82M, low $4.26M), average net income is $-150M (high $-69.92M, low $-248M), average SG&A $26.87M (high $43.87M, low $12.6M), and average EPS is $-0.51 (high $-0.237, low $-0.842).

Did the ABCL's actual financial results beat the analysts' financial forecasts?

Based on AbCellera Biologics's last annual report (Dec 2022), the company's revenue was $485.42M, beating the average analysts forecast of $399.1M by 21.63%. Apple's EBITDA was $276.25M, beating the average prediction of $182.8M by 51.12%. The company's net income was $158.52M, beating the average estimation of $129.55M by 22.37%. Apple's SG&A was $66.76M, missing the average forecast of $105.92M by -36.98%. Lastly, the company's EPS was $0.56, beating the average prediction of $0.474 by 18.17%. In terms of the last quarterly report (Sep 2023), AbCellera Biologics's revenue was $6.6M, missing the average analysts' forecast of $11.48M by -42.50%. The company's EBITDA was $-33.541M, missing the average prediction of $2.06M by -1727.38%. AbCellera Biologics's net income was $-28.61M, missing the average estimation of $-35.71M by -19.88%. The company's SG&A was $17.84M, beating the average forecast of $6.1M by 192.42%. Lastly, the company's EPS was $-0.0988, missing the average prediction of $-0.121 by -18.42%